IRA im­pact: As­traZeneca and Mer­ck CEOs warn of on­col­o­gy drug de­vel­op­ment shifts

This lat­est quar­ter­ly earn­ings sea­son for phar­ma has been a time for com­pa­nies to vent about Pres­i­dent Biden’s new drug price ne­go­ti­a­tion law, with some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.